Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2024; 20(1):175-181. doi:10.7150/ijbs.86305 This issue Cite

Review

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia

Jingnan Sun1, Ruiping Hu1, Mengyuan Han1, Yehui Tan1✉, Mengqing Xie1,3✉, Sujun Gao1✉, Ji-Fan Hu1,2✉

1. Hematology Department, First hospital of Jilin University, Changchun, Jilin, 130021, P.R. China.
2. Stanford University Medical School, Palo Alto Veterans Institute for Research, Palo Alto, CA94304, USA.
3. Oncology Department, Cancer hospital Chinese Academy of Medical Sciences, Langfang District, 065001, P.R. China.

✉ Corresponding authors: Ji-Fan Hu, Palo Alto Veterans Institute for Research, Palo Alto, CA 94304, USA, Tel: 650-852-3275, Fax: 650-849-1213, e-mail: jifanedu or hujifanedu.cn; or Sujun Gao, Hematology Department, First hospital of Jil More

Citation:
Sun J, Hu R, Han M, Tan Y, Xie M, Gao S, Hu JF. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci 2024; 20(1):175-181. doi:10.7150/ijbs.86305. https://www.ijbs.com/v20p0175.htm
Other styles

File import instruction

Abstract

Graphic abstract

Chronic myeloid leukemia (CML) is a malignant clonal disease involving hematopoietic stem cells that is characterized by myeloid cell proliferation in bone marrow and peripheral blood, and the presence of the Philadelphia (Ph) chromosome with BCR-ABL fusion gene. Treatment of CML has dramatically improved since the advent of tyrosine kinase inhibitors (TKI). However, there are a small subset of CML patients who develop resistance to TKI. Mutations in the ABL kinase domain (KD) are currently recognized as the leading cause of TKI resistance in CML. In this review, we discuss the concept of resistance and summarize recent advances exploring the mechanisms underlying CML resistance. Overcoming TKI resistance appears to be the most successful approach to reduce the burden of leukemia and enhance cures for CML. Advances in new strategies to combat drug resistance may rapidly change the management of TKI-resistant CML and expand the prospects for available therapies.

Keywords: chronic myeloid leukemia, TKI Resistance, ABL mutation, mechanism

Citation styles

APA
Sun, J., Hu, R., Han, M., Tan, Y., Xie, M., Gao, S., Hu, J.F. (2024). Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. International Journal of Biological Sciences, 20(1), 175-181. https://doi.org/10.7150/ijbs.86305.

ACS
Sun, J.; Hu, R.; Han, M.; Tan, Y.; Xie, M.; Gao, S.; Hu, J.F. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int. J. Biol. Sci. 2024, 20 (1), 175-181. DOI: 10.7150/ijbs.86305.

NLM
Sun J, Hu R, Han M, Tan Y, Xie M, Gao S, Hu JF. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci 2024; 20(1):175-181. doi:10.7150/ijbs.86305. https://www.ijbs.com/v20p0175.htm

CSE
Sun J, Hu R, Han M, Tan Y, Xie M, Gao S, Hu JF. 2024. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci. 20(1):175-181.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use